

Dear editor and reviewers,

Thank you very much for your useful recommendations.

We took into account all of them.

Reviewers:

In their report on six cases with KRAS mutated mCRC receiving CT plus bevacizumab treatment, the authors bring upon an important subject matter which is why some patients progress on CT plus bevacizumab while others benefit. Their finding concerning the possibility that the CXCL5 gene could be taking part in the resistance to bevacizumab is an important one which should be definitely investigated further. Concerning my comments, they are minor and are listed below. 1) concerning key words, please use MESH terms. **MESH terms have been used.**

2) define line 123 ALPSS. **ALPSS was defined.**

3) minor language errors: a)line 124-125: "In October 2017 and was admitted" change to "In October 2017, she was admitted..." b)line 143: "just for 3 months due to cardiac ischemia" change to "for only 3 months due to cardiac ischemia" c)line 154: "Patient characteristics were summarized in Table 1" change to "Patient characteristics are summarized in..." d)line 170-172: "Despite tumor progression" Please rephrase e)line 174: change "scare" to "scarce" f)line 175: replace "of the benefits" with "on the benefits".

All minor language errors were checked

4) I would suggest another table besides table 1 which would list each patient's case (case 1 through 6) with their CXCL5 value and their respective PFS. Then at the end of the table you could add the overall CXCL5 and PFS which you did in table 1.

Table 2 was done with PFS and CXCL5 expression values.

Editor:

The case report section was re-written and enlarged including the information and different aspects required in the guidelines.

We have also uploaded the approved grant application form (in Spanish) to the F6Publishing system. At this moment, due to Covid-19 our university is closed and we don't have access to the translation services. If you need this document in English, please don't hesitate to contact with us.

Sincerely,

Ana Fernández Santander, PhD

Universidad Europea de Madrid